EpiCARE Research Council – Current Grant Opportunities

Pre-proposal deadline: 10th of March 2026 14:00 CET

Link

Budget: The call will be conducted simultaneously by the respective national and regional funding organisations

The aim of the call is to facilitate multinational, collaborative and interdisciplinary research that addresses critical translational questions. Applications for this call, should address how biological, social and environmental factors affect the trajectory of neurological, mental and sensory disorders across the lifespan.

Applications must be interdisciplinary and address at least two of the three factors below:

1) Biological factors, e.g. genetics, epigenetics, -omics, neuroplasticity, inflammation,

infection, synaptogenesis, circuits, vascular factors, sensory impairment, co-morbidities;

2) Lifestyle and social factors, e.g. exercise/activity, nutrition, sleep, smoking, alcohol and drug abuse, work (income, employment), socio-economic background/status, race/ethnicity, sex and gender, education, safety, social interactions (family/friends), access to healthcare, stress, trauma, migration.

3) Environmental factors, e.g. pollution/contaminants, urbanicity, disasters, pandemics, war/conflicts, climate change, microbiota, nature.

In addition, applications must investigate at least two of the following aspects:

1) Mechanisms of action of the identified factors;

2) Early recognition, diagnosis and prognosis linked to the identified factors;

3) Prevention/treatments/interventions/technological development/care and support

linked to the identified factors.

Call published on 5 January 2026. 

Link

Budget: up to EUR 4 million, booster grants (EUR 50 000), coaching & mentoring, networking.

Deadline: 12 May 2026

What for?

Deep tech projects :Taking forward breakthrough deep tech projects with a high degree of scientific and technological ambition and risk and potential to create a new market (TRL 1-4)

Who can apply: Research teams ; Consortia of at least 3 different independent legal entities established in different countries or single applicants (Pathfinder Challenges only)

The EIC Pathfinder is a funding programme under Horizon Europe that offers support to research teams by:

• funding research to develop the scientific basis to underpin breakthrough technologies
• supporting the earliest stages of scientific, technological or deep-tech R&D
• aiming to build on new, cutting-edge directions in science and technology to disrupt a field and a market or create new opportunities
• realising innovative technological solutions to identify, develop and scale up breakthrough technologies and disruptive innovations in Europe

Requirements

Your proposal must meet all the following essential characteristics:

• Convincing long-term vision of a radically new technology that has the potential to have a transformative positive effect to solving a challenge in our economy and society
• Concrete, novel and ambitious science-towards-technology breakthrough, providing advancement towards the envisioned technology
• High-risk/high-gain research approach and methodology, with concrete and plausible objectives.

Call published on 5 January 2026. 

Link

Deadline: 12/05/2026

Budget: 96 M

to support coherent portfolios of projects within predefined thematic areas with the aim to achieve specific objectives for each Challenge

Challenge DeepRAP: Deep Reasoning, Abstraction & Planning towards trustworthy Cognitive AI Systems : To push scientific progress and help build a strong, collaborative community focused on practical applications of trustworthy cognitive AI.

Theis challenge will lay the groundwork for Europe’s future leadership in safe and human-centred AI, strengthening competitiveness and technological sovereignty, while supporting the goals of the AI Act and the European approach to Artificial Intelligence.

Call published on 5 January 2026. 

Opening: 10 Feb 2026

Deadline(s): 16 Apr 2026

Budget : 9.00 to 10.00 M

Link

Scope: The topic is focused on behavioural interventions for youth, defined as 12 to 25 years old, for the primary prevention of the top NCDs later in life, where “top NCDs” refers to the most prevalent NCDs. For the purpose of this call, NCDs explicitly exclude cancer.

Implementation research should be conducted to implement existing behavioural interventions.

These interventions should be evidence-based and have an emphasis on empowerment and self-management (e.g. health literacy, health education, health promotion). As self-monitoring is an essential element of self-management, proposals should include user- friendly hardware and software for efficient self-monitoring (i.e. wearables and point-of-care devices for measuring various physiological parameters and other predictors and other biomarkers and the corresponding apps for easy readout and tracking, possibly also including gamification elements). Hardware and software should be interoperable in line with internationally accepted standards in order to avoid lock-in effects and assure scalability.

Call published on 5 January 2026. 

Opening: 10 Feb 2026

Deadline(s): 16 Apr 2026

Budget: 1.50 to 1.90 M

Link

Scope: Life science innovations significantly contribute to peoples’ daily life and to individual and social well-being. To foster public trust, people must understand how life sciences work and how these technologies may impact people’s lives.

This trust is not guaranteed. It is increasingly threatened by the rapid spread of mis- and disinformation and by insufficient outreach to and involvement of people to address their concerns and expectations. To maintain and deepen trust, especially among young people, R&I policymakers, researchers and industry players must be better equipped to engage with the public and to pursue responsible research and innovation.

Proposals should address all the following activities:

• Provide advisory support and training to life science stakeholders, in order to upskill them in science communication and risk communication.
• Produce, publish and advertise to the relevant actors, guidance to engage citizens upstream in the development, co-production, and co-design of life sciences innovation.
• Produce, publish, and advertise to the relevant public an accessible repository of tools for life science stakeholders on risk communication.
• Design and run community engagement activities in the life sciences, in partnership with relevant local actors, such as science museums, R&I organisations, and/or community.

Call published on 5 January 2026. 

Opening: 10 Feb 2026

Deadline(s): 16 Apr 2026

Budget: 3 to 4 M

Link

Scope: The aim of this topic is to fund implementation research focused on strategies to tackle the growing burden of NCDs through actions in sectors and settings outside the traditional health system¹⁷³ and its facilities (with or without the involvement of the healthcare system) to attain equitable health-related outcomes or influence health determinants for people living in LMICs, and/or underserved populations in HICs.

Proposals can focus on more than one setting and/or include cross-sectoral approaches, involving both health and non-health settings to expand efforts to reduce risks, prevent, manage and control NCDs.

Applicants should explore the implementation of proposed intervention(s) for a selected study population(s) based in one or more LMICs, and/or underserved populations experiencing health disparities, including Indigenous populations, in HICs, considering the unique social, political, economic, and cultural context(s) in which the study will take place¹⁷⁵. Applicants should justify why any adaptation will not compromise the known effectiveness of the selected intervention(s).

Call published on 5 January 2026. 

Opening: 10 Feb 2026

Deadline(s): 16 Apr 2026

Budget : 3 to 8 M

Link

expected outcomes:

• Patients and their carers, health authorities and health professionals will benefit from the deployment of innovative solutions, designed around actual clinical needs, that facilitate identification, integration or coordination of care, allowing for personalised, more accessible, inclusive and higher quality of health and care.
• Patients will benefit from personalised approaches, improved care experiences and health outcomes or are more engaged in their care and better equipped to make informed decisions on their health, in collaboration with health professionals.
• Health professionals will be better equipped with, and thus benefit from, improved means for diagnosis, care delivery and/or coordination, with multi-disciplinary approaches and closer patient engagement, thanks to new technologies.
• Health systems will improve their accessibility, coordination mechanisms, effectiveness, inclusivity and resilience, thanks to innovative solutions, with a better use of resources, thus stimulating organisational innovation, cultural transformation within hospitals, and European-level collaboration.

PPI actions target consortia of procurers with a similar need that want to procure together the deployment of innovative solutions for supporting integration of care or diagnostics for personalised medicine. This topic does not provide direct funding to developers, industry or research organisations to perform research and development. They will be able to respond to the call for tenders launched by consortia of procurers funded under this topic.

Proposals should specify which segment of the patient population they target, the specific organisational and/or technological innovations to be procured, and why the proposed innovative solutions would be fit for purpose adhering, when relevant, to the principles of integrated care³¹⁸ or personalised medicine³¹⁹.

Examples of target groups that could be covered by this action are: patients at risk of vulnerability such as children and older/frail people with complex needs for health and social care; people with multi-morbidities or non-communicable diseases of high burden; people with both physical and mental health conditions; people living with rare diseases or cancer; persons with disabilities; other groups of patients in need of highly integrated and coordinated care. Proposals should pay attention to how gender and intersectional factors (e.g. caregiving responsibilities, work-related health disparities etc.) affect healthcare access and outcomes.

Proposals should demonstrate, with qualitative and quantitative indicators, how they contribute to the above expected outcomes, clearly describe the application of the principles of integrated care and personalised medicine in the deployed solutions, when relevant. This would also include embedding the innovation in the existing health systems, addressing gaps and avoiding overlaps, while fostering change management across organisations, professions and sectors.

Call published on 5 January 2026. 

Opening: 10 Feb 2026

Deadline(s): 16 Apr 2026

Budget: Around 10M

Link

expected outcomes:

• Healthcare providers and policymakers make use of evidence-based indicators and methodologies to identify low-value care ³²⁹ practices, as well as opportunities for improvement and tools to monitor such improvements.
• Healthcare professionals are equipped with the knowledge and tools to implement guidelines for reducing or discontinuing low-value care activities and maintaining effective and patient-centred practices that ensure quality of care.
• Patients and citizens benefit from more effective healthcare, by understanding and endorsing measures that reduce low-value care, recognising the potential to achieve higher-quality healthcare and better health outcomes overall.
• Health and care systems benefit from a reduction of low-value care practices, which enables enhanced patient safety and quality of care, while contributing to their efficiency as well as fiscal and environmental sustainability.
• Healthcare organisations can, by identifying low-value care practices, reallocate valuable healthcare resources to other areas of need.

Call published on 5 January 2026. 

Opening: 10 Feb 2026

Deadline(s): 16 Apr 2026

Budget: 5 to 8 M

Link

NAMs include a wide range of innovative and human-relevant technologies such as in-vitro or human ex-vivo assays, organoids, Organ-on-Chip (OoC) systems, human tissue models, induced Pluripotent Stem Cell (iPSC) applications, virtual twin tools, in-silico methods, and Artificial Intelligence (AI)-driven modelling.

expected outcomes:

• Researchers are in possession of improved human-relevant New Approach Methodologies (NAMs) platforms that capture the genetic, phenotypic, age-related, immune, microbiome, and environmental exposure variability of the human population. These innovations support more equitable healthcare solutions and personalised treatment strategies across diverse life stages.
• Industry gets access to platforms that allow a faster pace of innovation for the development of more cost-effective targeted therapeutic interventions and improvement of the safety assessment of chemicals, other medicinal products, and medical devices.
• Patients benefit from innovative platforms and strategies that improve prediction, prevention and treatment of diseases, in particular through enhanced understanding of disease pathways and mechanisms.
• The general population is better protected through a safer environment, as these platforms enhance the detection and mitigation of risks posed by chemicals and other potentially harmful substances.
• Regulatory bodies gain confidence and trust in NAMs, supporting their integration into product development, risk assessment, and approval processes.
• Fewer live animals are used in biomedical research and regulatory

Scope: This topic aims to support the ongoing paradigm shift in biomedical research and safety assessment of chemical compounds by fully integrating NAMs across the entire research and regulatory spectrum, from basic discovery phase to clinical application, and regulatory testing of medicinal products and medical devices, and/or industrial and environmental chemicals.

Call published on 5 January 2026. 

Opening: 10 Feb 2026

Deadline(s): 16 Apr 2026

Budget: Around 3.90 M

Link

The CoEs should directly support the development and manufacturing capacity of ATMP-related biotechnologies, such as cell and gene therapy platforms, manufacturing infrastructure, and scale-up processes.

Each potential CoE should be an existing centre embedded within a vibrant biocluster (i.e. within proximity to pharmaceutical companies and research institutes) and should already benefit from critical infrastructure and services necessary to advance from lab to patient such as knowledge transfer support, state-of-the-art GMP ³⁸¹ and clinical trials facilities. In addition, the centre should be performing the full spectrum of life sciences research, from discovery to clinical trials and should have demonstrated leadership in the field through a stand-alone research programme.

The proposed European network of CoEs for ATMPs should include multiple stakeholders beyond the research community and/or established academic centres, including Member State ministries, regional representatives, funders, regulators and healthcare payers, industry actors, patient organisations and policymakers. The European Commission’s Joint Research Centre (JRC) may participate as a member of the consortium selected for funding, bringing its expertise in pre-normative research, standardisation, regulatory advice and access to its research infrastructure.

Call published on 5 January 2026. 

Link 

The Twinning Call 2026 is designed to accelerate the implementation of personalised medicine (PM) solutions or approaches from one country to another through peer-to-peer exchanges.

This Call offers up to 50,000 EUR to activities that facilitate the exchange of solutions or approaches in personalised medicine and build up the capacities and capabilities of one or both participating parties. Twinning partnerships should last between 6 and 12 months.

Indicative Call Timeline

The Twinning process will begin with an initial “Early Matchmaking” phase opening on 13 October 2025. During this phase, both Twinning Donors with successful PM approaches in healthcare and Twinning Receivers with concrete PM needs and looking to implement PM approaches in their environment are invited to express their interest, establish primary contact, share ideas and begin collaboration on the Twinning Call proposal. The EP PerMed consortium will facilitate matchmaking opportunities through a designated matchmaking portal to link Twinning Donors and Twinning Receivers through the early matchmaking phase. Following this process, the official Twinning Call will be launched. In this step, pairs of donor and receiver(s) are expected to co-apply to the call.

A complementary online matchmaking event will take place on January 15th 2026, where Twinning Donors and Receiver organisations can present their successful personalised medicine approaches or personalised medicine needs in the form of a pitch to further facilitate the Twinning partnership matchmaking process.

Matchmaking Platform – opening on Monday 13 October, closing on Thursday 26 February

Call published on 28 November 2025. 

 Link

Budget: 14.8 Mio. € (approx.) (Indicative funding commitments of the participating organisations per country is available in the guidelines of the grant)

The call will be implemented in two stages, i.e. a pre- and a full proposal phase.

Expected timeline of the call

 Developing more personalised approaches through the integration of multimodal health data from multiple sources holds great potential to address the complex challenges of managing chronic disease and multimorbidity. To fully leverage this potential, there is an urgent need to find more efficient ways to utilise multimodal health data to support clinical decision-making, improve disease management and empower patients as active participants in their own care.

This call aims to bring together enterprises with clinical actors, including healthcare providers, patients, and researchers, to test innovative solutions in controlled real-world settings to address clear needs in managing multimorbidity.

EP PerMed will fund innovation projects in human health that focus on multimodal data usage for PM approaches aiming to provide more efficient and personalised management of patients with mul- timorbidity, having at least two chronic diseases that require management and adhere to the definition in the text box below.

Projects should address one or more of the following aspects:

• Detection or characterisation of co-morbidities in chronically ill patients.
• Diagnosis, follow-up or monitoring of disease progression, including remissions and relapses.
• Promoting a shift from in-patient to out-patient care through remote monitoring or reporting using wearables or other technical solutions.
• Decision support for disease intervention strategies (e.g., medication type and dosage).
• Tracking and managing multiple treatments (including drug combinations) to improve effectiveness or reduce adverse effects and potential harmful drug interactions.
• Adherence to long-term treatment regimens.

While clinical studies (exploratory/proof-of-concept/early stage clinical studies or sub-studies) can be funded in this call, larger clinical trials are out of scope.

Call published on 28 November 2025. 

On 10 December 2025, ERDERA will launch its 2026 Joint Transnational Call, “Resolving unsolved cases in rare genetic and non‑genetic diseases through variant validation and new technological approaches”. The call will welcome proposals focused on providing diagnostic clarity in unsolved rare genetic and non‑genetic diseases.

A detailed pre‑announcement is available here. It describes the forthcoming opportunity for multinational research teams to apply and will be updated with the full call when it launches.

An information webinar for potential applicants will take place on 16 December, 15:00–17:00 CET. Register for the webinar through this link.

Around 50% of individuals suspected of a rare genetic condition remain undiagnosed or misdiagnosed despite standard clinical genetics care, while an estimated 10% of rare diseases are non‑genetic and remain under‑investigated. This call aims to close those gaps by funding interdisciplinary collaborations that deliver diagnostic evidence and ultimately benefit patients and their families.

What the call will target

The call will support research that identifies causative variants in undiagnosed rare genetic diseases and addresses complex, multifactorial rare non‑genetic diseases, including patients with no molecular diagnosis after prior genetic or genomic testing.

Proposals should develop or apply approaches such as functional validation of variants of uncertain significance, integrative multi‑omics, advanced bioinformatics and AI‑enabled annotation, systems biology and disease‑mechanism modelling, and the integration of clinical, environmental, lifestyle and sensor‑derived data.

Developing knowledge graphs or disease maps and using state‑of‑the‑art modelling tools to link phenotypes with mechanisms are in scope. Pre‑clinical therapy development and interventional clinical trials are out of scope.

Who can apply and how consortia should be organised

Subject to national and regional rules, applications are open to academia, the clinical and public‑health sector, enterprises of all sizes (with encouragement for SMEs), and patient advocacy organisations.

Only transnational projects will be funded. Consortia must include four to six eligible principal‑investigator partners from at least four participating countries, with a maximum of two eligible partners per country; in specific cases, consortia may expand to eight partners. Patient partners, whether requesting funding or not, do not count towards the total.

A coordinator from an ERDERA JTC 2026 funding country or region, who must be an eligible project partner, will lead scientific coordination and reporting. Collaborators may join with their own resources, and subcontracting is possible where national rules allow; these roles do not count towards partner limits but must be described.

Why this matters and how it aligns with ERDERA

This call is part of ERDERA’s Funding workstream, which mobilises resources to accelerate high‑quality, cross‑border research with a clear path to benefit for people living with a rare disease.

By prioritising functional genomics, advanced data integration and robust analytical methods, the scheme aims to shorten diagnostic journeys and create evidence that informs care, research readiness and trial participation across Europe.

Patient and public involvement and engagement (PPIE) is embedded throughout the call: patient partners are expected from the outset, contribute to priority‑setting and study design, and take part in governance and reporting.

This ensures projects address patient‑need, improve inclusivity and deliver outputs that are more readily translated into clinical practice through ERDERA’s Clinical Research Network, Data Services Hub and Expertise Services Hub.

Key timeline at a glance

• The call is planned to open on 10 December 2025.
• An information webinar for potential applicants will take place on 16 December 2025, 15:00–17:00 CET.
• The pre‑proposal deadline is planned for 12 February 2026, with eligibility checks by 4 March and invitations to submit full proposals in early May.
• A second webinar for invited applicants is currently being planned for May.
• Full proposals are expected by 8 July 2026, with eligibility checks on 23 July and funding decisions notified in December 2026.

These dates are indicative and may change in the final call text.

Next steps

ERDERA will publish the full call text, national/regional annexes and submission links on the call page. The content and procedures outlined in this pre‑announcement may change and are not legally binding.

ERDERA’s priority remains enabling earlier diagnosis and better outcomes for people living with a rare disease through strong European collaboration.

Link

Opening date: 28/05/2026

Closing date 1: 27/08/2026

Budget: € 747 000 000 (projected number of awards: 294)

Are you an established, leading principal investigator who wants long-term funding to pursue a ground-breaking, ambitious project? The ERC Advanced Grant could be for you.

Who can apply?

Applicants for the ERC Advanced Grants – called Principal Investigators (PI) – are expected to be active researchers who have a track-record of significant research achievements.

The Principal Investigators should be exceptional leaders in terms of originality and significance of their research contributions. No specific eligibility criteria with respect to the academic requirements are foreseen.

Criteria
Applications can be made in any field of research.
The ERC’s grants operate on a ‘bottom-up’ basis without predetermined priorities.

Advanced Grants may be awarded up to € 2.5 million for a period of 5 years. (pro rata for projects of shorter duration). However, an additional € 1 million can be made available to cover eligible “start-up” costs for researchers moving from a third country to the EU or an associated country and/or the purchase of major equipment and/or access to large facilities and/or other major experimental and field work costs.

To further encourage the submission of excellent proposals by Principal Investigators currently based in non-associated third countries, the ERC has decided to double the amount of additional funding that can be awarded to Advanced Grant applicants moving to the EU or an associated country to take up their ERC grant. In this case, the maximum additional funding shall be € 2 million.

An ERC grant can cover up to 100% of the total eligible direct costs of the research plus a contribution of 25% of the total eligible costs towards indirect costs.

Link

Budget: Requests may be made for up to $125,000 for eighteen months.

The Taking Flight Award (1.5 years / $125,000) seeks to promote the careers of early-career investigators to allow them to develop an independent research focus.

You must fall into one of the following categories to be eligible for the Taking Flight Award:

• A postdoctoral fellow with a PhD, PsyD, PharmD, or equivalent and a minimum of two years postdoctoral experience at the time of submission
• A clinical fellow who is a Neurology Resident in his/her Neurology training and considering Epilepsy Fellowships
• Newly appointed faculty within one year of having completed postdoctoral training
• Clinician-researchers who are within two years of their faculty appointment

International applicants are welcome;

Link

The Rare Epilepsy Partnership Award (1 year / $100,000) will support the development of necessary research tools, techniques, model systems, and data collection platforms to stimulate and accelerate research on rare epilepsies. Each award will be co-funded by CURE Epilepsy and one or more of the rare epilepsy advocacy groups (partners) identified in the Request For Proposals. Applications must focus on one or more of the specific rare epilepsies that are represented by each group as well as address CURE Epilepsy’s mission to cure epilepsy.

The first ERDERA Clinical Trials Call will be soon available.

Link 

Clinical Trials Call funds controlled clinical research studies undertaken in humans to establish or confirm the safety and effectiveness of therapeutic interventions. These will benefit from ERDERA support for regulatory and methodological aspects.

Link 

Budget: one-year grants between $25,000 and $75,000.

The goal of the PCDH19 Alliance Research Grant Program is to fund research directly towards understanding the expression of the PCDH19 gene and the function of the PCDH19 protein, finding therapeutic treatments, and a cure for PCDH19 Epilepsy.
​
We also hope that the projects we fund will lead to additional research support from government or other funding agencies. We are pleased to be able to support many different types of projects, each critical for advancing all phases of PCDH19 research, from basic to clinical to treatment.

Link 

Budget : 13 Mio. € (approx.).

This call aims to bring together enterprises with clinical actors, including healthcare providers, patients, and researchers, to test innovative solutions in controlled real-world settings to address clear needs in managing multimorbidity.

EP PerMed will fund innovation projects in human health that focus on multimodal data usage for PM approaches providing more efficient and personalised management of multimorbid patients, having at least two chronic diseases that require management.

Projects will address one or more of the following aspects:

• Detection or characterisation of co-morbidities in chronically ill patients;
• Diagnosis, follow-up or monitoring of disease progression, including remissions and relapses;
• Promoting a shift from in-patient to out-patient care through remote monitoring or reporting using wearables or other technical solutions;
• Decision support for disease intervention strategies (e.g., medication type and dosage);
• Tracking and managing multiple treatments (including drug combinations) to improve effectiveness or reduce adverse effects and potential harmful drug interactions;
• Adherence to long-term treatment regimens.

Link

• Budget: Up to £80,000 for a maximum two-year project (opportunities for match funding may be sought)
• Usage: Funds are designated for salaries, project costs, and related expenses.
• Eligibility: Applicants must hold a permanent post at an eligible institution.
• Submission Limit: Only one application is permitted per centre.

Deadline: Applications accepted throughout the year

Link 

Travel costs and stipend

EMBO Scientific Exchange Grants contribute towards travel costs and subsistence of the fellow but not of any dependents. The subsistence rate depends on the country being visited. Research Exchange Grants do not provide additional funding for courses, conference travel, bench fees or overheads. EMBO does not cover visa costs.

Duration of support

The grants are intended for visits of one week (seven days) up to three months (90 days). Awarded applicants can stay on their research visit for an additional three months (maximum), however, EMBO will not provide funding for this extended period. It is possible to apply directly for more than three months (up to six), but the EMBO grant must be used for the first three months of the visit.

Budget: Projects may be funded at the $25,000, $50,000, or $75,000 level. The project duration is one or two years.

No deadline

Link

The Lennox-Gastaut Syndrome Foundation (LGS Foundation) is a non-profit organisation based in the United States. Its mission is to improve the lives of individuals affected by Lennox-Gastaut Syndrome, a rare form of childhood-onset epilepsy, through research, programmes and education. Projects may be on any novel topic in LGS but must be directly relevant to LGS, which is characterized by specific seizure types and hallmark EEG features.

The LGS Foundation Cure LGS 365 Research Grants provide funding to seed new basic, translational, and clinical Lennox-Gastaut Syndrome research projects.

Applications must be submitted by email. Letters of Intent (LOIs) may be submitted at any time; there are no deadlines. Selected applicants are invited to submit a full proposal.

Link

Deadlines: Project applications can be submitted until

• 1 February  for the summer meeting of the foundation committees in June
• 1 September for the winter meeting of the foundation committees in February

of each year.

In accordance with one of the desires of the donors, special attention is devoted by the foundation institutions to medical research. At present the foundation is focusing its support on the field of “Molecular causes in the development of illnesses”.  This programme supports molecular biological studies of illnesses whose development is based on genetic defects or with which gene variants contribute to the development of complex illnesses.

In the area of “Molecular causes in the development of illnesses”, molecular biological studies of illnesses are supported whose development is primarily based on genetic defects or whose gene variants contribute to the development of complex illnesses.

Studies may be performed on cell culture and/or animal models, but should at least in part be performed on human tissue specimens and/or cells bearing relevance to illnesses. This only applies for applications submitted for support of projects.

• Project proposals are only accepted from researchers that have a Ph.D. and relevant experience in the priority field of research. They should generally have two to four years’ experience in post-doctoral research and want to set up or expand a small working group of their own with the support of the Foundation. The position of the applicant should be funded by the host research Institute.
• It is generally not possible to obtain funding for one’s own position.
• Firmly established researchers and scientists (holders of chairs, directors of clinics) are not eligible for support of projects.

The following projects are assigned preference:

• The functional analysis of genes, gene products and their signal transduction pathways for monogenic and complex genetic illnesses in vitro and in vivo, whereby the work plan should also contain studies on human tissue specimens and/or cells
• The characterisation of cell and animal models that have already been established for the study of genetic illnesses (with molecular biology methods)
• The analysis of predisposing genes or therapies which modify illnesses (‘personalised medicine’) if this holds out the promise of additional findings being generated on the mechanistic causes of disease formation

Support is not provided for:

• Purely methodological studies
• Descriptive genetic studies of populations as well as linkage and association studies
• Purely drug screening projects
• Research projects without any direct connection to an illness
• Research projects involving the development of an animal model that is to be studied in the grant period applied for
• Research projects that do not involve any studies on human tissue specimens and/or cells bearing relevance to illnesses
• Research projects relating to infectious diseases
  Diagnostic and primarily therapy-oriented projects

TYPES OF COSTS

PERSONNEL COSTS

Complete personnel costs can be applied for in the case of research staff with doctoral degrees under

TVL-E13. In the case of research staff who do not have doctoral degrees, their pay is generally based on

65% of a TVL-E13-position. In countries other than Germany, the personnel costs are to be stated

according to the salary costs arrangements applicable there, i.e. total wage costs including the employer’s

share as a total sum.

In the case of applying for personnel costs for clinician scientists, the foundation assumes that the

planned staff will be put on leave at least 80 per cent of their working time at the clinic. Confirmation of

this from the clinic is to be submitted with the application.

Non-academic personnel are paid at the appropriate TVL level.

Student helpers or research assistants should be paid according to the rates prevailing at the institution

involved; the foundation is to be notified hereof through the budget plan accompanying the application.

TRAVEL COSTS

Funds to defray travel costs that are directly connected with the project can be applied for. In addition to

reasonable travel and overnight accommodation costs, up to € 28 a day can be granted to defray the costs

of meals when traveling within Germany (rail travel 2nd class or air travel economy class).

In the case of travel abroad, the daily or monthly rates for the respective country of travel can be applied

for to defray overnight accommodation and meal costs.

WHAT CANNOT BE APPLIED FOR

› Staff resources for the own post

› Financial resources for construction work

› Financial resources to procure office furnishings and equipment that are usually part of the basic

furnishings at universities and institutes

› Generally, no financial resources are granted to defray overhead costs

The FamilieSCN2A Hodgkin-Huxley Grant program was created to honor the achievements of Dr. Alan Hodgkin and Dr. Andrew Huxley and their innovative modeling of action potentials, as well as their contributions which laid the groundwork for neuroscience research on the molecular, cellular, and circuit levels.

Unsolicited, year-round LOIs accepted. Full application invitations on a rolling basis as long as funds are available.

Link

Link

These research grant awards are intended for established, experienced, independent investigators affiliated with a research or academic institution whose proposed projects seek to investigate hypotheses directly related to hypothalamic hamartoma syndrome. Proposals are scored based on the quality of preliminary data, research design, feasibility, investigator’s qualifications, and overall impact.

Investigators applying for a research grant should ensure their proposed project addresses the needs of the hypothalamic hamartoma syndrome community and Hope for HH’s mission to support research toward better understanding, improved treatments and ultimately a cure for hypothalamic hamartoma syndrome.

Eligibility:

Applicants should be affiliated with a research or academic institution (excluding for-profit companies), may be US or foreign based, established in their field, and in good standing with their institution.

Our research priority areas include:

• Research that helps identify patient trends, characteristics, epidemiology, or other clinical aspects of hypothalamic hamartoma syndrome and/or its comorbidities.
• Research that will encourage the development of novel therapies to eliminate or prevent seizure progression or halt the progression of other comorbidities associated with hypothalamic hamartoma syndrome.
• Research that helps to understand, predict, and prevent SUDEP